JP2023537895A5 - - Google Patents
Info
- Publication number
- JP2023537895A5 JP2023537895A5 JP2023507508A JP2023507508A JP2023537895A5 JP 2023537895 A5 JP2023537895 A5 JP 2023537895A5 JP 2023507508 A JP2023507508 A JP 2023507508A JP 2023507508 A JP2023507508 A JP 2023507508A JP 2023537895 A5 JP2023537895 A5 JP 2023537895A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- composition according
- fatty liver
- alcoholic fatty
- liver disease
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR10-2020-0102604 | 2020-08-14 | ||
| KR20200102604 | 2020-08-14 | ||
| PCT/KR2021/010780 WO2022035271A1 (ko) | 2020-08-14 | 2021-08-13 | 삼중 활성체 지속형 결합체를 유효성분으로 포함하는 약학 조성물 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2023537895A JP2023537895A (ja) | 2023-09-06 |
| JP2023537895A5 true JP2023537895A5 (enExample) | 2024-08-20 |
Family
ID=80247218
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023507508A Pending JP2023537895A (ja) | 2020-08-14 | 2021-08-13 | 三重活性体持続型結合体を有効成分として含む薬学組成物 |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20230302148A1 (enExample) |
| EP (1) | EP4197560A4 (enExample) |
| JP (1) | JP2023537895A (enExample) |
| KR (1) | KR20220021890A (enExample) |
| AU (1) | AU2021324792A1 (enExample) |
| CA (1) | CA3187742A1 (enExample) |
| IL (1) | IL299800A (enExample) |
| MX (1) | MX2023001599A (enExample) |
| TW (1) | TW202220700A (enExample) |
| WO (1) | WO2022035271A1 (enExample) |
| ZA (1) | ZA202301081B (enExample) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4197550A4 (en) * | 2020-08-14 | 2025-10-08 | Hanmi Pharmaceutical Co Ltd | PHARMACEUTICAL COMPOSITION WITH HYPOTENSIVE EFFECT COMPRISING A TRIPLE ACTIVATOR WITH ACTIVITY FOR ALL GLUCAGON, GLP-1, AND GIP RECEPTORS |
| KR20230004135A (ko) * | 2021-06-30 | 2023-01-06 | 한미약품 주식회사 | 글루카곤, glp-1 및 gip 수용체 모두에 활성을 갖는 삼중 활성체를 포함하는 조합물의 치료학적 용도 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6096871A (en) | 1995-04-14 | 2000-08-01 | Genentech, Inc. | Polypeptides altered to contain an epitope from the Fc region of an IgG molecule for increased half-life |
| JP4046354B2 (ja) | 1996-03-18 | 2008-02-13 | ボード オブ リージェンツ，ザ ユニバーシティ オブ テキサス システム | 増大した半減期を有する免疫グロブリン様ドメイン |
| WO2012088379A2 (en) * | 2010-12-22 | 2012-06-28 | Marcadia Biotech, Inc. | Methods for treating metabolic disorders and obesity with gip and glp-1 receptor-active glucagon-based peptides |
| KR102041412B1 (ko) * | 2011-12-30 | 2019-11-11 | 한미사이언스 주식회사 | 면역글로불린 Ｆｃ 단편 유도체 |
| CN104583232B (zh) * | 2012-06-21 | 2018-04-13 | 印第安纳大学研究及科技有限公司 | 展现gip受体活性的胰高血糖素类似物 |
| CN105829339B (zh) * | 2013-11-06 | 2021-03-12 | 西兰制药公司 | 胰高血糖素-glp-1-gip三重激动剂化合物 |
| SG11201805586SA (en) * | 2015-12-31 | 2018-07-30 | Hanmi Pharmaceutical Co Ltd | Triple glucagon/glp-1/gip receptor agonist |
| TWI767095B (zh) * | 2017-12-21 | 2022-06-11 | 美商美國禮來大藥廠 | 腸促胰島素(incretin)類似物及其用途 |
| EP4197550A4 (en) * | 2020-08-14 | 2025-10-08 | Hanmi Pharmaceutical Co Ltd | PHARMACEUTICAL COMPOSITION WITH HYPOTENSIVE EFFECT COMPRISING A TRIPLE ACTIVATOR WITH ACTIVITY FOR ALL GLUCAGON, GLP-1, AND GIP RECEPTORS |
-
2021
- 2021-08-13 EP EP21856277.5A patent/EP4197560A4/en active Pending
- 2021-08-13 CA CA3187742A patent/CA3187742A1/en active Pending
- 2021-08-13 JP JP2023507508A patent/JP2023537895A/ja active Pending
- 2021-08-13 MX MX2023001599A patent/MX2023001599A/es unknown
- 2021-08-13 IL IL299800A patent/IL299800A/en unknown
- 2021-08-13 WO PCT/KR2021/010780 patent/WO2022035271A1/ko not_active Ceased
- 2021-08-13 KR KR1020210107599A patent/KR20220021890A/ko active Pending
- 2021-08-13 AU AU2021324792A patent/AU2021324792A1/en active Pending
- 2021-08-13 US US18/040,869 patent/US20230302148A1/en active Pending
- 2021-08-13 TW TW110129971A patent/TW202220700A/zh unknown
-
2023
- 2023-01-25 ZA ZA2023/01081A patent/ZA202301081B/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US10159714B2 (en) | Compositions, devices and methods of use thereof for the treatment of cancers | |
| JP2005523946A5 (enExample) | ||
| JP2024532619A5 (enExample) | ||
| JP2023537895A5 (enExample) | ||
| JP2025179059A (ja) | アクチビン受容体ｉｉ型キメラ及びその使用方法 | |
| EP3212217A1 (en) | Compositions and peptides having dual glp-1r and glp-2r agonist activity | |
| JP2017538395A5 (enExample) | ||
| BG64288B1 (bg) | 'ъ''ави на ов 'ля' про'...ин и м...'оди за 'яхно'о пол"-аван... | |
| EP1425028A2 (en) | Use of il-18 inhibitors for the treatement or prevention of sepsis | |
| JP2024540275A5 (enExample) | ||
| IL291681B2 (en) | Therapeutic use of trigonal glucagon/glp-1/gip receptor agonist or conjugate thereof for liver disease | |
| JP2021514354A5 (enExample) | ||
| JP2023502005A5 (enExample) | ||
| JP2023551877A5 (enExample) | ||
| JP2025518227A (ja) | ｍａｚｄｕｔｉｄｅを使用する治療方法 | |
| JP2024178193A (ja) | インスリン及びグルカゴンを含む薬学組成物 | |
| JP2024500605A5 (enExample) | ||
| JP2009540842A5 (enExample) | ||
| JPH03503647A (ja) | 黒色腫の治療のためのｉｌ‐２とｄｔｉｃとの組合せ療法 | |
| JP2024544057A5 (enExample) | ||
| JP2023057328A (ja) | 自己免疫性疾患治療効果を有するオリゴヌクレオチドおよびそのオリゴヌクレオチドを含有する自己免疫性疾患治療薬 | |
| JP2024527220A5 (enExample) | ||
| EP4687946A1 (en) | Methods and uses for treating nausea and emesis | |
| JP2022513438A5 (enExample) | ||
| JP2021535911A (ja) | 一酸化窒素感応性を有するアクリルアミド系高分子を含む炎症性疾患の予防または治療用薬学組成物 |